Debt-to-equity of Eiger BioPharmaceuticals, Inc. from 30 Sep 2016 to 31 Dec 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Eiger BioPharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 31 Dec 2023.
  • Eiger BioPharmaceuticals, Inc. Debt-to-equity for the quarter ending 31 Dec 2023 was 672%, a 808% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Eiger BioPharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2023 672% +598% +808% 31 Dec 2023
Q3 2023 233% +166% +246% 30 Sep 2023
Q2 2023 136% +75% +123% 30 Jun 2023
Q1 2023 94% +37% +66% 31 Mar 2023
Q4 2022 74% +23% +46% 31 Dec 2022
Q3 2022 67% +21% +44% 30 Sep 2022
Q2 2022 61% +16% +34% 30 Jun 2022
Q1 2022 57% +5.6% +11% 31 Mar 2022
Q4 2021 51% -13% -21% 31 Dec 2021
Q3 2021 47% -27% -37% 30 Sep 2021
Q2 2021 46% -36% -44% 30 Jun 2021
Q1 2021 51% -21% -29% 31 Mar 2021
Q4 2020 64% -4.7% -6.8% 31 Dec 2020
Q3 2020 74% +12% +20% 30 Sep 2020
Q2 2020 81% +16% +24% 30 Jun 2020
Q1 2020 72% +3.3% +4.9% 31 Mar 2020
Q4 2019 69% -1% -1.4% 31 Dec 2019
Q3 2019 62% -21% -25% 30 Sep 2019
Q2 2019 65% -22% -25% 30 Jun 2019
Q1 2019 69% -47% -40% 31 Mar 2019
Q4 2018 70% -23% -25% 31 Dec 2018
Q3 2018 83% +6% +7.8% 30 Sep 2018
Q2 2018 87% +42% +94% 30 Jun 2018
Q1 2018 115% +87% +311% 31 Mar 2018
Q4 2017 93% +74% +389% 31 Dec 2017
Q3 2017 77% +58% +311% 30 Sep 2017
Q2 2017 45% 30 Jun 2017
Q1 2017 28% 31 Mar 2017
Q4 2016 19% 31 Dec 2016
Q3 2016 19% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.